This article is more than 5 years old. Information may no longer be current.

Study confirms early positive results of glaucoma treatment device

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Preliminary findings from the EyeMUST study have confirmed the positive results of a pilot study on a glaucoma treatment device, according to a news release from EyeTechCare.

The EyeOP1 device was used on 60 glaucoma patients at nine centers in France. It is an ultrasonic instrument that is designed to deliver a noninvasive treatment for refractory glaucoma that can be administered on an outpatient basis.

There were no major side effects in the study, and eyes showed few signs of inflammation with no postoperative IOP spikes or pain in more than 95% of patients. Up to 90% of patients responded favorably to the Ultrasonic Circular Cyclo-Coagulation method with an average IOP reduction of 42% to 49%.

Efficacy was shown in advanced glaucoma patients who have undergone unsuccessful interventions, take a large number of medications and have a high initial IOP.

EyeTechCare has begun the international EyeMUST2 study with 120 patients at 12 centers in six countries. The first results are expected in early 2013.